

DETAILED ACTION

1. Claim 1 as amended by Examiner's amendment is allowable. Accordingly, the election of species requirement, as set forth in the Office action mailed on 04/21/08, has been reconsidered in view of the allowability of claims to the elected invention. **The election of species requirement is hereby withdrawn as to any claim that requires all the limitations of an allowable claim.** Accordingly, claims 3-5, directed to non-elected species, are no longer withdrawn from consideration because the claim(s) requires all the limitations of an allowable claim.
2. Receipt is acknowledged of Sequence Listing filed on 03/19/2009. It has been placed in the application file (available in the SCORE database).
3. Receipt is acknowledged of papers, ITALY TO2002A000684, submitted under 35 U.S.C. 119(a)-(d), which papers have been placed of record in the file.

EXAMINER'S AMENDMENT

4. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Susan J. Mack on April 03, 2009.

The application has been amended as follows:

In the Claims:

In claim 1, lines 7-10, delete [optionally substituted linear and angular coumarins, optionally substituted heteroanalogues of angelicin, thiopyrano-benzofurans, acylangelicins, alkylangelicins, alkoxycarbamoylangelicins, and optionally substituted psoralens and isopsoralens] and replace with --an acylangelicin, an alkylangelicin, an alkoxycarbamoylangelicin and bergapten--.

In claim 4, lines 3, add --, wherein the further modifier of the transcription process is selected from the group consisting of cytosine arabinoside, retinoic acid, plicamycin, mithramycin, hydroxyurea, guanine, guanosine triphosphate (GTP), guanosine diphosphate (GDOP) and guanosine monophosphate (GMP)-- after "process".

Claims 3 and 5 are cancelled.

Reasons for Allowance

5. The following is an examiner's statement of reasons for allowance: The prior art reference(s) alone or in combination (Nagai et al. and Naeff et al.) in which the rejection of record is relied upon fail(s) to teach or suggest the use of angelicin, acylangelicin, alkylangelicin, alkoxycarbamoylangelicin and bergapten for the treatment of beta-thalassemia.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue

fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

6. Claims 1 and 4 are allowed.
7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brian Kwon whose telephone number is (571) 272-0581. The examiner can normally be reached Tuesday through Friday from 9:00 am to 7:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel, can be reached on (571) 272-0718. The fax number for this Group is (571) 273-8300.

Any inquiry of a general nature of relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (571) 272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications may be obtained from Private PAIR only. For more information about PAIR system, see <http://pair-direct.uspto.gov> Should you have any questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll free).

/Brian-Yong S Kwon/
Primary Examiner, Art Unit 1614

